
## Xiao-Li Wei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6837951/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy. JAMA Network Open, 2022, 5, e220587.	5.9	23
2	Toripalimab plus chemotherapy in treatment-naÃ⁻ve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell, 2022, 40, 277-288.e3.	16.8	177
3	Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210901.	1.3	4
4	Current status and advances of immunotherapy in nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210962.	3.2	23
5	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterology Report, 2021, 9, 560-570.	1.3	10
6	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198899.	3.2	17
7	Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. Journal of Medical Genetics, 2021, , jmedgenet-2020-107230.	3.2	11
8	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). Journal of Clinical Oncology, 2021, 39, 704-712.	1.6	156
9	A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. Leukemia, 2021, 35, 3212-3222.	7.2	15
10	Development and Validation of a Prognostic Classifier Based on Lipid Metabolism–Related Genes in Gastric Cancer. Frontiers in Molecular Biosciences, 2021, 8, 691143.	3.5	22
11	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature Medicine, 2021, 27, 1536-1543.	30.7	197
12	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase lb/II clinical trial and gut microbiome analysis. Cell Reports Medicine, 2021, 2, 100383.	6.5	49
13	The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. Oncolmmunology, 2021, 10, 1938381.	4.6	10
14	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. American Journal of Cancer Research, 2021, 11, 5006-5015.	1.4	0
15	Prospective observation: Clinical utility of plasma Epstein–Barr virus DNA load in EBVâ€associated gastric carcinoma patients. International Journal of Cancer, 2020, 146, 272-280.	5.1	41
16	Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. Theranostics, 2020, 10, 498-515.	10.0	68
17	Observational cohort study of clinical outcome in Epstein–Barr virus associated gastric cancer patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093743.	3.2	16
18	Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients. Frontiers in Oncology, 2020, 10, 563407.	2.8	5

XIAO-LI WEI

#	Article	IF	CITATIONS
19	PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. Journal of Translational Medicine, 2020, 18, 475.	4.4	23
20	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clinical and Translational Medicine, 2020, 10, 353-362.	4.0	13
21	A phase I study of toripalimab, an antiâ€PDâ€1 antibody, in patients with refractory malignant solid tumors. Cancer Communications, 2020, 40, 345-354.	9.2	30
22	Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Communications, 2019, 39, 1-12.	9.2	1,177
23	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	9.2	418
24	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	5.1	34
25	A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. Cell Death Discovery, 2018, 4, 116.	4.7	16
26	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. Journal of Cancer, 2018, 9, 4325-4333.	2.5	16
27	Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. International Journal of Cancer, 2017, 141, 152-159.	5.1	38
28	Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. Theranostics, 2017, 7, 4836-4849.	10.0	265
29	Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment. BioMed Research International, 2017, 2017, 1-8.	1.9	37
30	<em>FcγRIIA</em> and <em>IIIA </em> polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. OncoTargets and Therapy, 2017, Volume 10, 5065-5076.	2.0	11
31	Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications. Theranostics, 2016, 6, 1160-1175.	10.0	75
32	The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumor Biology, 2016, 37, 1879-1887.	1.8	33
33	The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy. Oncotarget, 2016, 7, 75094-75103.	1.8	23
34	A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer, 2015, 15, 350.	2.6	126
35	Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer. PLoS ONE, 2014, 9, e89965.	2.5	17
36	Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 18404.	3.3	38

XIAO-LI WEI

#	Article	IF	CITATIONS
37	The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. Journal of Translational Medicine, 2013, 11, 249.	4.4	34
38	The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer. PLoS ONE, 2013, 8, e83921.	2.5	27
39	ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. International Journal of Cancer, 2012, 131, 461-468.	5.1	102
40	DNA polymerasel̂· protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. Journal of Translational Medicine, 2010, 8, 126.	4.4	53
41	Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer, 2008, 8, 115.	2.6	56
42	High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007, 109, 1360-1364.	4.1	119